COMMON STOCK PURCHASE WARRANT LIXTE BIOTECHNOLOGY HOLDINGS, INC.Common Stock Purchase Warrant • March 2nd, 2021 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on [●] (the “Termination Date”) but not thereafter, to subscribe for and purchase from LIXTE BIOTECHNOLOGY HOLDINGS, INC., a Delaware corporation (the “Company”), up to [●] shares, par value $0.0001, of the Company (the “Common Stock”) (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 2nd, 2021 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of February 26, 2021, and is between Lixte Biotechology Holdings,, Inc, a corporation incorporated under the laws of the state of Delaware (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
